PF-8380 is a selective inhibitor of diacylglycerol lipase (DAGL), an enzyme involved in the biosynthesis of 2-arachidonoylglycerol (2-AG), one of the major endocannabinoid signaling molecules. Its primary application lies in research settings, where it is used to investigate the role of the endocannabinoid system, particularly 2-AG pathways, in physiological and pathological processes. It has been utilized in studies related to neuroinflammation, pain modulation, and neurodegenerative diseases such as Alzheimer's and Parkinson's. By reducing 2-AG levels, PF-8380 helps researchers dissect the contribution of this endocannabinoid in synaptic transmission, immune response in the central nervous system, and metabolic regulation. Additionally, PF-8380 has shown potential in cancer research, where inhibition of DAGL affects tumor cell migration and invasion, especially in models of breast and brain cancers. Its ability to modulate lipid signaling makes it a valuable tool compound for probing lipid metabolism and developing targeted therapies, although it is not used clinically and remains restricted to preclinical investigation.